TIMP1, TIMP metallopeptidase inhibitor 1, 7076

N. diseases: 603; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.560 Biomarker disease BEFREE MMP-2, MMP-9, and TIMP-1 accumulation were quantified to evaluate the lung fibrosis exposure to PQ. 26129822 2016
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.560 Biomarker disease BEFREE TIMP1 promotes multi-walled carbon nanotube-induced lung fibrosis by stimulating fibroblast activation and proliferation. 27852133 2017
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.560 Biomarker disease BEFREE OCA administration, even after the establishment of PF, significantly improved pulmonary function, normalizing PAO, and reverted the bleomycin-induced lung alterations, with significant reduction of markers of inflammation (CD206, COX2, HIF1, IL1β, MCP1), epithelial proliferation (CTGF, PDGFa) and fibrosis (COL1A1, COL3A1, ET1, FN1, MMPs, αSMA, SNAIs, TGFβ1, TIMPs). 29923060 2019
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.560 AlteredExpression disease BEFREE These results demonstrate that FBP may prevent bleomycin-induced PF development through reduced expression of collagen and other ECM components mediated by a reduced TIMP-1 and MMP2 expression. 31509566 2019
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.560 Biomarker disease CTD_human In conclusion, unbalanced MMP/TIMP-1 expression and excessive gelatinolytic activity contribute to PQ-induced pulmonary fibrosis. 21468558 2011
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.560 Biomarker disease BEFREE IL-33 can regulate deposition of ECM and promote the process of pulmonary fibrosis by inducing the imbalance between MMP-9 and TIMP-1. 29417309 2018
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.560 AlteredExpression disease BEFREE Intranasal administration of curcumin significantly inhibited airway inflammation and pulmonary fibrosis, where MMP-9 activities were decreased along with α-smooth muscle actin (α-SMA), MMP-9, TIMP-1, and eotaxin expressions. 27866296 2017
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.560 Therapeutic disease RGD Inhibitory effects of alkaline extract of Citrus reticulata on pulmonary fibrosis. 23318412 2013
CUI: C0011853
Disease: Diabetes Mellitus, Experimental
Diabetes Mellitus, Experimental 		0.500 Biomarker disease RGD [Modulative effect of zhenqing recipe on expressions of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in experimental type 2 diabetic rats]. 17569353 2006
CUI: C0011853
Disease: Diabetes Mellitus, Experimental
Diabetes Mellitus, Experimental 		0.500 Biomarker disease CTD_human Altered matrix metalloproteinases and tissue inhibitors of metalloproteinases in embryos from diabetic rats during early organogenesis. 21963884 2011
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental 		0.500 Biomarker disease RGD Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. 8707259 1996
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental 		0.500 Biomarker disease CTD_human Cytokine blockade inhibits hepatic tissue inhibitor of metalloproteinase-1 expression and up-regulates matrix metalloproteinase-9 in toxic liver injury. 16762003 2006
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental 		0.500 Biomarker disease CTD_human Systems level analysis and identification of pathways and networks associated with liver fibrosis. 25380136 2014
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental 		0.500 Biomarker disease CTD_human Correlation between TIMP-1 expression and liver fibrosis in two rat liver fibrosis models. 16718785 2006
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental 		0.500 Biomarker disease CTD_human Heme oxygenase-1 regulates the major route involved in formation of immune hepatic fibrosis in rats. 21163135 2010
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental 		0.500 Biomarker disease CTD_human Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. 16507762 2006
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.350 Biomarker disease BEFREE This study was aimed to investigate the efficacy of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), and the neutrophil gelatinase-associated lipocalin (NGAL)-bound form of MMP-9 (MMP-9/NGAL complex) markers in the determination of early nephropathy in patients with type 2 diabetes mellitus. 30367022 2018
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.350 Biomarker disease CTD_human Type 2 diabetes is characterised by reduced monocyte TIMP-1 mRNA levels, and a lower plasma MMP-9 to TIMP-1 protein ratio compared to controls, a pattern that would promote coronary plaque instability if reproduced within vascular plaque. 16023759 2006
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.350 AlteredExpression disease BEFREE The presence of type 2 diabetes associated with 3.2-fold increased PAI-1 expression (adjusted p=0.033), while the presence of hypertension associated with about 50% reduction of IL-8 and TIMP-1. 25496999 2015
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.350 AlteredExpression disease BEFREE Type 2 diabetes is characterised by reduced monocyte TIMP-1 mRNA levels, and a lower plasma MMP-9 to TIMP-1 protein ratio compared to controls, a pattern that would promote coronary plaque instability if reproduced within vascular plaque. 16023759 2006
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.350 Biomarker disease BEFREE TIMP-1 is independently associated with myocardial diastolic dysfunction in patients with Type 2 diabetes mellitus. 28685602 2017
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.350 Biomarker disease BEFREE Circulating MMP2,9, the inhibitor TIMP-1 and C-reactive protein (CRP) were measured during studies of vitamin-D deficiency as a risk factor for type 2 diabetes and CHD in 171 healthy British Bangladeshi adults, free of known diabetes or major illness. 12454321 2002
CUI: C0029172
Disease: Oral Submucous Fibrosis
Oral Submucous Fibrosis 		0.320 AlteredExpression disease BEFREE We concluded that increased mRNA expression of TIMP-1 in buccal mucosal fibroblasts by arecoline and safrole is a possible pathogenesis for oral submucous fibrosis. 12907213 2003
CUI: C0029172
Disease: Oral Submucous Fibrosis
Oral Submucous Fibrosis 		0.320 Biomarker disease CTD_human Oral submucous fibrosis: review on aetiology and pathogenesis. 16311067 2006
CUI: C0029172
Disease: Oral Submucous Fibrosis
Oral Submucous Fibrosis 		0.320 Biomarker disease BEFREE Targeting S100A4 might be a potential therapeutic target for OSF through TIMP1/MMP9 down-regulation. 23383075 2013